...
首页> 外文期刊>Antiviral therapy >Inluence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women
【24h】

Inluence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women

机译:感染艾滋病毒的孕妇在怀孕前进行短期产前抗逆转录病毒治疗对病毒载量和母婴传播的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: HIV-infected women not requiring treatment for their own health usually receive short-course antiretroviral therapy (ART) during pregnancy. Little is known about the effect of this on response to HAART in subsequent pregnancies. Methods: We analysed data from the UK and Ireland's National Study of HIV in Pregnancy and Childhood for 2000-2010. Analyses were restricted to live births among women not on ART at conception but receiving antenatal HAART. We compared risk of detectable viral load at delivery and mother-to-child transmission in two pregnancy groups: 'ART-naive' and 'HAART-experienced' (=7 days of HAART during previous pregnancy). Multivariable analyses were conducted using logistic regression. Results: There were 5,372 pregnancies in the ART-naive group and 605 in the HAART-experienced group. Overall, there was weak evidence of an increased risk of detectable viral load in the HAART-experienced group (adjusted odds ratio [aOR] 1.27; 95% CI 1.01, 1.60); however, the increased risk was apparent only among women who previously received non-nucleoside reverse transcriptase inhibitorbased HAART (aOR 1.81; 95% CI 1.25, 2.63), and not among those with previous protease-inhibitor-based HAART exposure (aOR 1.08; 95% CI 0.81, 1.45). There was no difference in mother-to-child transmission risk between the ART-naive and HAART-experienced groups (aOR 0.42; 95% CI 0.10, 1.78), although the number of transmissions was small. Conclusions: We found no increased risk of detectable viral load at delivery among women exposed to shortcourse, protease-inhibitor-based HAART during a previous pregnancy. However, women with prior exposure to non-nucleoside reverse transcriptase inhibitor-based HAART appeared to be at increased risk of not adequately suppressing the virus. These indings highlight the need for careful management of HIV-infected women presenting with repeat pregnancies.
机译:背景:HIV感染的妇女无需为自身健康而接受治疗,通常在怀孕期间接受短程抗逆转录病毒疗法(ART)。关于其在随后的妊娠中对HAART反应的影响知之甚少。方法:我们分析了来自英国和爱尔兰的《 2000-2010年艾滋病毒在孕期和儿童期国家研究》中的数据。分析仅限于在妊娠时未接受抗逆转录病毒治疗但接受产前HAART的妇女中的活产。我们比较了两个妊娠组在分娩时和母婴传播时可检测到的病毒载量的风险:“未接受过ART”和“经历过HAART”(在先前妊娠中= 7天的HAART)。使用逻辑回归进行多变量分析。结果:初次接受ART的组有5,372例怀孕,有HAART的组有605例。总体而言,在有HAART经验的组中,几乎没有证据表明可检测到病毒载量的风险增加(校正后的优势比[aOR] 1.27; 95%CI 1.01、1.60);但是,仅在以前接受过非核苷类逆转录酶抑制剂的HAART的女性(aOR 1.81; 95%CI 1.25,2.63)中增加了患病风险,而在以前接受过蛋白酶抑制剂的HAART暴露的女性中则无明显风险(aOR 1.08; 95) %CI 0.81、1.45)。初次接受抗逆转录病毒治疗和有HAART经验的组之间的母婴传播风险没有差异(aOR 0.42; 95%CI 0.10,1.78),尽管传播的次数很少。结论:我们发现在先前怀孕期间暴露于短程,基于蛋白酶抑制剂的HAART的妇女中,分娩时可检测到病毒载量的风险没有增加。但是,事先接触过基于非核苷类逆转录酶抑制剂的HAART的妇女似乎面临不能充分抑制该病毒的高风险。这些说明突出表明,需要认真管理有反复怀孕现象的艾滋病毒感染妇女。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号